Clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory viral infections.
NorthLinks Bio is advancing its lead intranasal candidate HEX17 toward Phase 2b readiness and maintains research operations in St Andrews, Scotland following a reorganization from Pneumagen Ltd.